Immune Pharmaceuticals Inc. (IMNP) 3.38 $IMNP
Anaplastic Thyroid Cancer Therapeutics Pipeline Review 2014 - 7 Companies & 11 Drug profiles
M2 - Wed Sep 24, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9mkn9d/anaplastic) has announced the addition of the "Anaplastic Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Anaplastic Thyroid Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Anaplastic Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Anaplastic Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Plexxikon Inc. - Exelixis, Inc. - OXiGENE, Inc. - Genelux Corporation - Immune Pharmaceuticals, Inc. Drug Profiles - fosbretabulin tromethamine - efatutazone - cabozantinib s-malate - crolibulin - (dabrafenib mesylate trametinib dimethyl sulfoxide) - PLX-8394 - GLONC-2 - PLX-4720 - CLM-3 - CLM-94 - AY-4 For more information visit http://www.researchandmarkets.com/research/9mkn9d/anaplastic
Immune Pharmaceuticals Initiates Phase II Clinical Trial In Ulcerative Colitis
PR Newswire - Thu Sep 18, 1:30AM CDT
Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company"
announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC).
IPOs and Transactions: September 8 - 12
PR Newswire - Mon Sep 15, 1:23PM CDT
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
Immune Pharmaceuticals Presenting At The 16th Annual Rodman & Renshaw Global Investment Conference, September 10, 2014
PR Newswire - Mon Sep 08, 6:00AM CDT
Immune Pharmaceuticals Inc. (NASDAQ and NASDAQ OMX First North Premier, Stockholm: "IMNP"; "Immune" or "the Company" , today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at the New York Palace Hotel in New York City.
Amorfix appoints Dr Elliot Goldstein and Mr Warren Whitehead to Board of Directors
CNW Group - Thu Sep 04, 6:30AM CDT
Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that it has appointed Dr. Elliot Goldstein and Mr. Warren Whitehead to its Board of Directors.
OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing
PR Newswire - Thu Aug 21, 7:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM) congratulates Immune Pharmaceuticals Inc., a biotechnology company, on its approval to list on The NASDAQ Capital Market. Immune previously traded on OTCQX®, the best marketplace for established U.S. and global companies operated by OTC Markets Group.
Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market
PR Newswire - Tue Aug 19, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP" , a biotechnology company, today announced that it has received confirmation that its application to list its common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market, a unit of the NASDAQ OMX Group. IMMUNE's common stock is expected to begin trading on the NASDAQ Capital Market at the opening of trading on August 21, 2014 under the symbol IMNP.
Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
PR Newswire - Thu Aug 14, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP" , announced today its operating results for the quarter ended June 30, 2014.
Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin
PR Newswire - Wed Jul 30, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP."; "Immune" or "the Company" announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of moderate to severe bullous pemphigoid. This open-label trial will enroll 10-15 patients who will receive two bertilimumab infusions, at a dose of 10 mg/kg, on days 0 and 14. Patients will also start concomitant treatment with an initial moderate dose of oral prednisone (30 mg daily) to be tapered down rapidly starting as early as week 1 based on patient response. Patients will be followed for eight weeks with primary efficacy end points focused on disease control measured by the Bullous Pemphigoid Disease Area Index, a validated index developed by international experts in this indication, and steroid sparing, the proportion of patients who achieve a steroid dose of full story)
OTC Trading Stock News: Digipath, Inc. Immune Pharmaceuticals, Inc. Vuzix Corp, Nuvilex, Inc. Origin Oil, Inc.
PR Newswire Europe - Tue Jul 29, 7:07AM CDT
LONDON, July 29, 2014 /PRNewswire/ --
Immune Appoints Cameron Durrant, MD, MBA to Board of Directors
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company" appointed Dr. Cameron Durrant as new independent director. Dr. Durant becomes a Member of the Compensation Committee and the R&D Committee.
OTC Stocks Trading News: Fannie Mae, Immune Pharmaceuticals, Inc. Cannabis Sativa, Inc. United Cannabis Corp, Cynk Technology Corp.
PR Newswire Europe - Thu Jul 10, 7:01AM CDT
LONDON, July 10, 2014 /PRNewswire/ --
IMMUNE Partners With Patient Community Group LYFEBULB
GlobeNewswire - Wed Jun 25, 1:30AM CDT
Lyfebulb, an organization dedicated to helping people achieve their optimal lifestyle by addressing general and chronic health concerns, and Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) co-hosted the third Lyfebulb event on June 19th at Brasserie Ruhlmann in New York. The event provided an opportunity for guests to connect and learn about emerging and personalized therapies in Crohn's and Colitis Disease, also known as Inflammatory Bowel Disease (IBD). The event's host committee included Lyfebulb founder and renowned health and wellness expert, Dr. Karin Hehenberger, Dr. Daniel Teper, the CEO of Immune Pharmaceuticals, and Dr. James Aisenberg, distinguished gastroenterologist and Associate Clinical Professor of Medicine at The Mount Sinai Hospital.
Immune CEO Announces New Operational Leadership Team
GlobeNewswire - Wed Apr 02, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today the addition of two new senior members to its management team.
Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors
M2 - Fri Mar 14, 4:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvnwqx/competitor) has announced the addition of the "Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors" report to their offering. The present Competitive Intelligence Report about EGF-R Antibodies -Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted combined 2013 sales of US$ 2,486 mln. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies. The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered 1. EGF-R Antibodies -Biosimilars and Biosuperiors Marketed EGF-R Antibodies - Erbitux Sales & Pipeline - Vectibix Sales & Pipeline - Nimotuzumab Pipeline EGF-R Antibody Biobetters/Biosuperiors - Engineered EGF-R Antibodies - Bi- and Multispecific EGF-R Antibodies - EGF-R Antibody-Drug Conjugates EGF-R Antibody Biosimilars - Cetuximab Biosimilars - Panitumumab Biosimilars 2. Corporate EGF-R Antibody Biosimilar & Biobetter Pipelines Companies Mentioned - AbbVie - Actavis - Amgen - Avesthagen Pharma - Biocon - BioXpress - Bristol-Myers Squibb (BMS) - Celltrion - Centro de Imunologica Molecular AB (CIMAB) - CytomX Therapeutics - Daiichi Sankyo - Eli Lilly - Fusion Therapeutics - Glycotope - Green Cross - Hospira - Immune Pharmaceuticals - Immunogen - Innogene Kalbiotech - InnoMab - ISU Abxis - Janssen Pharmaceuticals - Med Discover - Merck GKaA - Merrimack Pharmaceuticals - Merus - Oncobiologics - Oncoscience - Pfizer 4 - PharmaPraxis - PlantForm - Roche - Shanghai Zhangjiang Biotechnology - Sorrento Therapeutics - Symphogen - Takeda Pharmaceutical - Viropro - Zyngenia For more information visit http://www.researchandmarkets.com/research/vvnwqx/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.
IMMUNE Pharmaceuticals to Present at the 16th BIO CEO & Investor Conference
Marketwire - Thu Feb 06, 4:45PM CST
IMMUNE Pharmaceuticals Inc. (OTCQX: IMNP) (NASDAQ: IMNP) announced today that Daniel Teper, Chairman and Chief Executive Officer, will be presenting at the 16th annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 11:30AM local time at the Waldorf Astoria, Room Duke of Windsor, in New York.
Anaplastic Thyroid Cancer Therapeutics Pipeline Review 2014 - 7 Companies & 11 Drug profiles
M2 - Wed Sep 24, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9mkn9d/anaplastic) has announced the addition of the "Anaplastic Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Anaplastic Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Anaplastic Thyroid Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Anaplastic Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Anaplastic Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Plexxikon Inc. - Exelixis, Inc. - OXiGENE, Inc. - Genelux Corporation - Immune Pharmaceuticals, Inc. Drug Profiles - fosbretabulin tromethamine - efatutazone - cabozantinib s-malate - crolibulin - (dabrafenib mesylate trametinib dimethyl sulfoxide) - PLX-8394 - GLONC-2 - PLX-4720 - CLM-3 - CLM-94 - AY-4 For more information visit http://www.researchandmarkets.com/research/9mkn9d/anaplastic
Immune Pharmaceuticals Initiates Phase II Clinical Trial In Ulcerative Colitis
PR Newswire - Thu Sep 18, 1:30AM CDT
Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company"
announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC). IPOs and Transactions: September 8 - 12
PR Newswire - Mon Sep 15, 1:23PM CDT
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
Immune Pharmaceuticals Presenting At The 16th Annual Rodman & Renshaw Global Investment Conference, September 10, 2014
PR Newswire - Mon Sep 08, 6:00AM CDT
Immune Pharmaceuticals Inc. (NASDAQ and NASDAQ OMX First North Premier, Stockholm: "IMNP"; "Immune" or "the Company"
, today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at the New York Palace Hotel in New York City. Amorfix appoints Dr Elliot Goldstein and Mr Warren Whitehead to Board of Directors
CNW Group - Thu Sep 04, 6:30AM CDT
Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that it has appointed Dr. Elliot Goldstein and Mr. Warren Whitehead to its Board of Directors.
OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing
PR Newswire - Thu Aug 21, 7:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM) congratulates Immune Pharmaceuticals Inc., a biotechnology company, on its approval to list on The NASDAQ Capital Market. Immune previously traded on OTCQX®, the best marketplace for established U.S. and global companies operated by OTC Markets Group.
Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market
PR Newswire - Tue Aug 19, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP"
, a biotechnology company, today announced that it has received confirmation that its application to list its common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market, a unit of the NASDAQ OMX Group. IMMUNE's common stock is expected to begin trading on the NASDAQ Capital Market at the opening of trading on August 21, 2014 under the symbol IMNP. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
PR Newswire - Thu Aug 14, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP"
, announced today its operating results for the quarter ended June 30, 2014. Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin
PR Newswire - Wed Jul 30, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: "IMNP."; "Immune" or "the Company"
announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of moderate to severe bullous pemphigoid. This open-label trial will enroll 10-15 patients who will receive two bertilimumab infusions, at a dose of 10 mg/kg, on days 0 and 14. Patients will also start concomitant treatment with an initial moderate dose of oral prednisone (30 mg daily) to be tapered down rapidly starting as early as week 1 based on patient response. Patients will be followed for eight weeks with primary efficacy end points focused on disease control measured by the Bullous Pemphigoid Disease Area Index, a validated index developed by international experts in this indication, and steroid sparing, the proportion of patients who achieve a steroid dose of full story) OTC Trading Stock News: Digipath, Inc. Immune Pharmaceuticals, Inc. Vuzix Corp, Nuvilex, Inc. Origin Oil, Inc.
PR Newswire Europe - Tue Jul 29, 7:07AM CDT
LONDON, July 29, 2014 /PRNewswire/ --
Immune Appoints Cameron Durrant, MD, MBA to Board of Directors
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company"
appointed Dr. Cameron Durrant as new independent director. Dr. Durant becomes a Member of the Compensation Committee and the R&D Committee. OTC Stocks Trading News: Fannie Mae, Immune Pharmaceuticals, Inc. Cannabis Sativa, Inc. United Cannabis Corp, Cynk Technology Corp.
PR Newswire Europe - Thu Jul 10, 7:01AM CDT
LONDON, July 10, 2014 /PRNewswire/ --
IMMUNE Partners With Patient Community Group LYFEBULB
GlobeNewswire - Wed Jun 25, 1:30AM CDT
Lyfebulb, an organization dedicated to helping people achieve their optimal lifestyle by addressing general and chronic health concerns, and Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) co-hosted the third Lyfebulb event on June 19th at Brasserie Ruhlmann in New York. The event provided an opportunity for guests to connect and learn about emerging and personalized therapies in Crohn's and Colitis Disease, also known as Inflammatory Bowel Disease (IBD). The event's host committee included Lyfebulb founder and renowned health and wellness expert, Dr. Karin Hehenberger, Dr. Daniel Teper, the CEO of Immune Pharmaceuticals, and Dr. James Aisenberg, distinguished gastroenterologist and Associate Clinical Professor of Medicine at The Mount Sinai Hospital.
Immune CEO Announces New Operational Leadership Team
GlobeNewswire - Wed Apr 02, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today the addition of two new senior members to its management team.
Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors
M2 - Fri Mar 14, 4:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvnwqx/competitor) has announced the addition of the "Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors" report to their offering. The present Competitive Intelligence Report about EGF-R Antibodies -Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted combined 2013 sales of US$ 2,486 mln. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies. The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered 1. EGF-R Antibodies -Biosimilars and Biosuperiors Marketed EGF-R Antibodies - Erbitux Sales & Pipeline - Vectibix Sales & Pipeline - Nimotuzumab Pipeline EGF-R Antibody Biobetters/Biosuperiors - Engineered EGF-R Antibodies - Bi- and Multispecific EGF-R Antibodies - EGF-R Antibody-Drug Conjugates EGF-R Antibody Biosimilars - Cetuximab Biosimilars - Panitumumab Biosimilars 2. Corporate EGF-R Antibody Biosimilar & Biobetter Pipelines Companies Mentioned - AbbVie - Actavis - Amgen - Avesthagen Pharma - Biocon - BioXpress - Bristol-Myers Squibb (BMS) - Celltrion - Centro de Imunologica Molecular AB (CIMAB) - CytomX Therapeutics - Daiichi Sankyo - Eli Lilly - Fusion Therapeutics - Glycotope - Green Cross - Hospira - Immune Pharmaceuticals - Immunogen - Innogene Kalbiotech - InnoMab - ISU Abxis - Janssen Pharmaceuticals - Med Discover - Merck GKaA - Merrimack Pharmaceuticals - Merus - Oncobiologics - Oncoscience - Pfizer 4 - PharmaPraxis - PlantForm - Roche - Shanghai Zhangjiang Biotechnology - Sorrento Therapeutics - Symphogen - Takeda Pharmaceutical - Viropro - Zyngenia For more information visit http://www.researchandmarkets.com/research/vvnwqx/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.
IMMUNE Pharmaceuticals to Present at the 16th BIO CEO & Investor Conference
Marketwire - Thu Feb 06, 4:45PM CST
IMMUNE Pharmaceuticals Inc. (OTCQX: IMNP) (NASDAQ: IMNP) announced today that Daniel Teper, Chairman and Chief Executive Officer, will be presenting at the 16th annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 11:30AM local time at the Waldorf Astoria, Room Duke of Windsor, in New York.
